{"preliminary_commentary":{"by_channel":{"x_thread":17,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05756153\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-22T14:51:28.358Z","note":"Automated from all 21 indexed sources (Nov 2023 – Apr 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":21,"text":"- Whether a chemotherapy-free fulzerasib-cetuximab regimen can replace PD-1-based first-line therapy, alone or with chemotherapy\n- Whether the combination controls brain metastases in KRAS G12C NSCLC\n- Whether PD-L1 or EGFR expression predicts benefit from fulzerasib plus cetuximab\n- Whether cetuximab blocks EGFR feedback and delays adaptive resistance to KRAS G12C inhibition","kind":"questions"},"drugs_tested":[["fulzerasib","cetuximab"]],"indication":"previously untreated advanced KRAS G12C-mutated NSCLC","name":"KROCUS","nct_id":"NCT05756153","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=krocus-nct05756153. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"GFH925+Cetuximab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-04-30","type":"ACTUAL"},"conditions":["Advance Non-small Cell Lung Cancer"],"enrollment":{"count":47,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"GFH925","otherNames":[],"type":"DRUG"},{"name":"Cetuximab","otherNames":[],"type":"DRUG"}],"last_update":"2025-08-12","lead_sponsor":"Genfleet Therapeutics (Shanghai) Inc.","official_title":"A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-04-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase Ib: adverse events","timeFrame":"28 days"},{"measure":"Phase II: objective response rate","timeFrame":"up to 1 year after last patient in"}],"references":[{"citation":"Gregorc V, Majem M, Lo Russo G, Maio M, Salvagni S, Gutierrez-Calderon V, Gonzalez-Cao M, Sandiego Contreras S, Koumarianou A, Bearz A, Bernabe-Caro R, Viteri S, de Sanmamed MF, Zagouri F, Moran Bueno T, Lazzari C, Martinez-Recio S, Gimenez-Capitan A, Zhang Y, Shan Y, Zhu H, Zhao C, Shen H, Wang Y, Rosell R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. Lancet Oncol. 2026 Apr;27(4):432-441. doi: 10.1016/S1470-2045(25)00764-8.","pmid":"41926959","type":"DERIVED"}],"start_date":{"date":"2023-04-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation","url":"https://clinicaltrials.gov/study/NCT05756153"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/krocus-nct05756153"}